TruScreen Group (ASX:TRU, NZE:TRU) has re-entered the Indian market with the appointment of Renovate Biologicals as distributor of its artificial intelligence-enabled cervical cancer screening product, according to a Wednesday New Zealand and Australian bourse filing.
The company said its technology is non-invasive and may be preferred by certain subgroups as it does not require a collection of cervical cells, the filing said.